Boston Children's Hospital, Boston, MA
Brent Weil , Arin L Madenci , Qi Liu , Todd M. Gibson , Yutaka Yasui , Joseph Philip Neglia , Wendy M. Leisenring , Rebecca M. Howell , Emily S. Tonorezos , Danielle Novetsky Friedman , Christopher Tinkle , Lisa Diller , Gregory T. Armstrong , Kevin C. Oeffinger , Christopher Bertero Weldon
Background: Asplenia or hyposplenism can develop in survivors of childhood cancer following splenectomy or radiotherapy exposure to the left upper quadrant of the abdomen (LUQ). Knowledge regarding long-term infection related outcomes for these survivors is limited. Methods: Infection related late mortality (sepsis, meningitis or pneumonia) was evaluated in 20,805 5-year survivors (diagnosed <21 years of age from 1970-1999, median follow-up 26 years, range 5-44) using cumulative incidence and Poisson regression models to calculate adjusted relative risk (RR) and 95% confidence intervals (CI). Average LUQ radiation was calculated as a surrogate for splenic radiation. Results: Treatment included splenectomy for 1328 survivors (6%). An additional 10,295 (49%) were exposed to LUQ radiotherapy without splenectomy. The cumulative incidence of infection related late mortality was 1.4% (95%CI: 0.7%-2.2%) at 35 years after splenectomy and 0.6% (95%CI: 0.4%-0.8%) after LUQ radiotherapy, with a total of 78 deaths attributable to infectious causes (25 sepsis, 1 meningitis, 52 pneumonia). Splenectomy (RR=8.4, p<0.001) and increasing LUQ radiotherapy dose (p<0.001) were independently associated with infection related late mortality (Table). Conclusions: Splenectomy and LUQ radiotherapy increased risk for infection related late mortality. While infectious mortality increased with increasing LUQ radiation dose, even lower dose exposure (<10Gy) increased risk substantially. Accordingly, cancer survivors exposed to LUQ radiotherapy should be considered at risk for functional asplenia and managed similarly to asplenic individuals with respect to vaccinations and febrile illnesses.
Treatment | RR (95% CI) | P |
---|---|---|
No splenectomy; no RT (Ref.) | 1.0 | |
Splenectomy | 8.4 (3.5 - 20.1) | <0.001 |
No splenectomy, 0.1-10 Gy LUQ RT | 2.4 (1.1 - 5.2) | 0.028 |
No splenectomy, 10-19 Gy LUQ RT | 6.1 (2.5 – 14.9) | <0.001 |
No splenectomy, 20+ Gy LUQ RT | 9.3 (3.2 – 27.0) | <0.001 |
*Adjusted for age at diagnosis, attained age, sex, race and chronic health conditions. RT, radiotherapy.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Rusha Bhandari
2022 ASCO Annual Meeting
First Author: Todd M. Gibson
2022 ASCO Annual Meeting
First Author: Peter de Blank
2023 ASCO Annual Meeting
First Author: Amanda Janitz